Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen M Hahn

Showing results (161-170 of 180) with videos related to

Pageof 18
Sort By:
Plos One|August 7, 2009
Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacyGeorge J Cerniglia, Nabendu Pore, Jeff H Tsai, et al.
Cancer|February 26, 2013
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancerPhillip J Gray, Jonathan J Paly, Beow Y Yeap, et al.
Frontiers in Immunology|March 5, 2019
Role of Radiation Therapy in Modulation of the Tumor Stroma and MicroenvironmentHari Menon, Rishab Ramapriyan, Taylor R Cushman, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 18, 2012
Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patientsLilie L Lin, Antti Silvoniemi, James B Stubbs, et al.
JAMA Oncology|August 23, 2019
Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 TrialRamesh Rengan, Rosemarie Mick, Daniel A Pryma, et al.
JAMA Oncology|April 26, 2019
Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 TrialQuynh-Nhu Nguyen, Stephen G Chun, Edward Chow, et al.
Cancer|March 28, 2017
7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trialBing Sun, Eric D Brooks, Ritsuko U Komaki, et al.
Global Health, Science and Practice|December 28, 2020
Capturing Acquired Wisdom, Enabling Healthful Aging, and Building Multinational Partnerships Through Senior Global Health MentorshipC Norman Coleman, John E Wong, Eugenia Wendling, et al.
Clinical Lung Cancer|October 20, 2018
Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor LocationCaitlin A Schonewolf, Marina Heskel, Abigail Doucette, et al.
JAMA Network Open|January 16, 2019
Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung CancerEric D Brooks, Bing Sun, Lei Feng, et al.
Pageof 18

Showing results (161-170 of 180) with videos related to

Sort By:
Pageof 18
Plos One|August 7, 2009
Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacyGeorge J Cerniglia, Nabendu Pore, Jeff H Tsai, et al.
Cancer|February 26, 2013
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancerPhillip J Gray, Jonathan J Paly, Beow Y Yeap, et al.
Frontiers in Immunology|March 5, 2019
Role of Radiation Therapy in Modulation of the Tumor Stroma and MicroenvironmentHari Menon, Rishab Ramapriyan, Taylor R Cushman, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 18, 2012
Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patientsLilie L Lin, Antti Silvoniemi, James B Stubbs, et al.
JAMA Oncology|August 23, 2019
Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 TrialRamesh Rengan, Rosemarie Mick, Daniel A Pryma, et al.
JAMA Oncology|April 26, 2019
Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 TrialQuynh-Nhu Nguyen, Stephen G Chun, Edward Chow, et al.
Cancer|March 28, 2017
7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trialBing Sun, Eric D Brooks, Ritsuko U Komaki, et al.
Global Health, Science and Practice|December 28, 2020
Capturing Acquired Wisdom, Enabling Healthful Aging, and Building Multinational Partnerships Through Senior Global Health MentorshipC Norman Coleman, John E Wong, Eugenia Wendling, et al.
Clinical Lung Cancer|October 20, 2018
Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor LocationCaitlin A Schonewolf, Marina Heskel, Abigail Doucette, et al.
JAMA Network Open|January 16, 2019
Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung CancerEric D Brooks, Bing Sun, Lei Feng, et al.
Pageof 18